HDAC and MAPK/ERK Inhibitors Cooperate to Reduce Viability and Stemness Phenotype in Medulloblastoma Running title: HDAC and MAPK/ERK in medulloblastoma

1 Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPEHCPA), Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil, 2 Children’s Cancer Institute, Porto Alegre, RS, Brazil, 3 Bioinformatics Core, Experimental Research Center, Clinical Hospital (CPE-HCPA), Porto Alegre, RS, Brazil, 4 The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, ON, Canada, 5 Developmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, ON, Canada, 6 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 7 Division of Neurosurgery, The Hospital for Sick Children, Toronto, ON, Canada, 8 Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada, 9 Department of